Institute Receives Support to Establish Excellence in Biopharma

The Indian Institute of Technology (IIT Delhi) and Agilent Technologies have recently signed an understanding that will promote biopharmaceutical research. Under the agreement Agilent will contribute funds to support the IIT Delhi incubator in establishing global best practices for identifying and characterising biopharmaceuticals. The research conducted by IIT Delhi examines and reports on the quality of biotherapeutic products for the Indian market.

At the signing, Agilent CEO Mike McMullen spoke about the company’s history of innovation, focus on research and academia and the vision for the future; Prof. V. Ramgopal Rao, the Institute’s Director spoke about its mission and role in promoting collaborations between academia and industry.

We are happy to be associated with Agilent,” said Prof. Anurag S. Rathore (IIT Delhi), Coordinator of the Institutes’s Centre of Excellence for Biopharmaceutical Technology (CBT). “Agilent’s broad range of technologies will further boost our efforts at the Centre of Excellence for Biopharmaceutical Technology. This mutually constructive and productive partnership will hopefully lead to promising results for the entire biotherapeutics ecosystem.”

“We are excited to embark on this initiative with IIT Delhi, an institute with the country’s brightest minds engaged in research and technology,” said Bharat Bhardwaj, country general manager, Agilent India. “Agilent’s relationship with IIT Delhi goes back decades. The new memorandum of understanding that we have signed will further strengthen our relationship and will enhance the ability to do cutting-edge research, which can be used to improve the quality of life for the community at large, through the application of new innovations.”